Fast Market Research

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2015 - New Market Report

Fast Market Research announces the availability of the new Global Markets Direct report, "Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2015", on their comprehensive research portal


Boston, MA -- (SBWIRE) -- 10/01/2015 -- Global Markets Direct's, 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2015', provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and special features on late-stage and discontinued projects.

Get More Details on this Report and a Full Table of Contents at Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


-The report provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in the therapeutics development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and enlists all their major and minor projects
-The report summarizes all the dormant and discontinued pipeline projects
-A review of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-A detailed assessment of monotherapy and combination therapy pipeline projects
-Coverage of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type
-Latest news and deals relating related to pipeline products

Reasons to Get This Report

-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Develop strategic initiatives by understanding the focus areas of leading companies
-Identify and understand important and diverse types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
-Devise corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline depth and focus of Indication therapeutics
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned in this Report: 4SC AG, AB Science SA, AbbVie Inc., Acetylon Pharmaceuticals, Inc., Actinium Pharmaceuticals, Inc., Advenchen Laboratories, LLC, Affichem SA, Agios Pharmaceuticals, Inc., AIMM Therapeutics B.V., Akinion Pharmaceuticals AB, Altor BioScience Corporation, Amgen Inc., Antigen Express, Inc., APIM Therapeutics AS, Aprea AB, Aptose Biosciences Inc., Ariad Pharmaceuticals, Inc., Arno Therapeutics, Inc., Arog Pharmaceuticals, Inc., Array BioPharma Inc., Ascenta Therapeutics, Inc., Astellas Pharma Inc., Astex Pharmaceuticals, Inc., AstraZeneca Plc, Atara Biotherapeutics, Inc., AVEO Pharmaceuticals, Inc., Bayer AG, BerGenBio AS, BIND Therapeutics, Inc., Bio-Cancer Treatment International Limited, Bio-Path Holdings, Inc., BioInvent International AB, BioLineRx, Ltd., Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Calithera Biosciences, Inc., Cancer Therapeutics CRC Pty Ltd, Cantargia AB, Cantex Pharmaceuticals, Inc., Celator Pharmaceuticals, Inc., Celgene Corporation, Cellceutix Corporation, Celldex Therapeutics, Inc., Cellectis S.A., Cellerant Therapeutics, Inc., Celyad, Clevexel Pharma SAS, Constellation Pharmaceuticals, Inc., Cornerstone Pharmaceuticals, Inc., Critical Outcome Technologies Inc., CTI BioPharma Corp., CureTech Ltd., Cyclacel Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, DC Prime B.V., Debiopharm International S.A., Deciphera Pharmaceuticals, LLC, DiNonA Inc., Egenix, Inc., Eisai Co., Ltd., Eli Lilly and Company, EntreChem, S.L., EpiZyme, Inc., Erytech Pharma SA, Esperance Pharmaceuticals, Inc., Eureka Therapeutics, Inc., Exelixis, Inc., F. Hoffmann-La Roche Ltd., Fate Therapeutics, Inc., Formula Pharmaceuticals, Inc., Fortress Biotech, Inc., Fujifilm Corporation, Gamida Cell Ltd., Genentech, Inc., Genoscience Pharma, Genosco, Genzyme Corporation, Gilead Sciences, Inc., GlaxoSmithKline Plc, GlycoMimetics, Inc., Golden Biotechnology Corp., Hybrigenics S.A., Igenica Biotherapeutics, Inc., Ignyta, Inc., Immune System Key Ltd., ImmunGene, Inc., ImmunoGen, Inc., Inbiopro Solutions Pvt. Ltd., Incyte Corporation, Interprotein Corporation, Jasco Pharmaceuticals, LLC., Jiangsu Hansoh Pharmaceutical Co., Ltd., Johnson & Johnson, Juno Therapeutics Inc., JW Pharmaceutical Corporation, Kainos Medicine, Inc., KaloBios Pharmaceuticals, Inc., Karyopharm Therapeutics, Inc., Kiadis Pharma B.V., Kinex Pharmaceuticals, LLC, Kolltan Pharmaceuticals, Inc., Komipharm International Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Lead Discovery Center GmbH, Les Laboratoires Servier SAS, MacroGenics, Inc., MaxCyte, Inc., medac GmbH, MediGene AG, MedImmune, LLC, MEI Pharma, Inc., Merck & Co., Inc., Merus B.V., Millennium Pharmaceuticals, Inc., Mirna Therapeutics, Inc., MolMed S.p.A., NantKwest, Inc., Nerviano Medical Sciences S.r.l., Neumedicines Inc., Novartis AG, NuCana BioMed Limited, OncoImmune, Inc., Onconova Therapeutics, Inc., Ono Pharmaceutical Co., Ltd., Onyx Pharmaceuticals, Inc., Otsuka Holdings Co., Ltd., Oxford BioTherapeutics Ltd, OXiGENE, Inc., Pfizer Inc., Pharma Mar, S.A., Pharmacyclics, Inc., Pharmedartis GmbH, Philogen S.p.A., Polaris Pharmaceuticals, Inc., Resverlogix Corp., Rich Pharmaceuticals, Inc., Sanofi, Sareum Holdings Plc, Seattle Genetics, Inc., Sellas Inc., Selvita SA, Senhwa Biosciences, Inc., Sentinel Oncology Limited, Sorrento Therapeutics, Inc., SpectraMab GmbH, Stemline Therapeutics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Sunesis Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc., SYNIMMUNE GmbH, Synta Pharmaceuticals Corp., Syros Pharmaceuticals, Inc., TaiGen Biotechnology Co., Ltd., Tautatis Incorporated, TetraLogic Pharmaceuticals, Teva Pharmaceutical Industries Limited, Theravectys SA, Threshold Pharmaceuticals, Inc., Toko Pharmaceutical Industries Co., Ltd., Tolero Pharmaceuticals, Inc., Tragara Pharmaceuticals, Inc., Trillium Therapeutics Inc., Verastem, Inc., Vichem Chemie Research Ltd., VioQuest Pharmaceuticals, Inc., Viralytics Ltd., Xencor, Inc.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2014
-Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2015
-Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014
-Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015
-Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2014